



13 February 2025

Company Announcements Office
Australian Securities Exchange

Notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth)

Cambium Bio Limited (the "**Company**") refers to its announcement on 5 December 2024, regarding a placement of shares to sophisticated institutional and private investors of 6,361,875 ordinary shares to raise AUD\$ 2,950,001.44.

The Company has today settled on part of the placement and issued 862,627 fully paid ordinary shares at an issue price of AUD\$ 0.4637 per share.

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**) that:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
2. as at the date of this notice the Company has complied with:
 - (a) the provisions of Chapter 2M of the *Corporations Act* as they apply to the Company; and
 - (b) section 674 of the *Corporations Act*; and
3. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) and 708A(8) of the *Corporations Act*) which is required to be disclosed by the Company.

An Appendix 2A with respect to the issue has been lodged with ASX.

Authorised for release by the Board of Directors of Cambium Bio Limited.

A handwritten signature in black ink, appearing to read "H. Leung", with a stylized flourish at the end.

Helen Leung
Company Secretary
Cambium Bio Limited